OncologyTube Professional - Patients Click Here
Genitourinary-Cancer-Meeting
23,586 video views
Loading........
Description: Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD...
04:08
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-fre​e survival by PD-L1 group at the 2018 ASCO.
01:28
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy at the 2018 ASCO.
01:25
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses tUsing Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements at the 2018 ASCO.
04:30
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO.
01:33
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
01:22
Tony Choueiri, MD of Dana Farber discusses CheckMate 025 phase III trial at ASCO GU 2016
00:37
Robert Dreicer, MD of the University of Virginia Health System discusses immunotherapy in non muscle invasive bladder cancer at ASCO GU 2016.
00:38
Robert Dreicer, MD of the University of Virginia Health System discusses the how soon should we expect approval of immunotherapy in urothelial cancer at ASCO GU 2016.
00:44
Robert Dreicer, MD of the University of Virginia Health System discusses the future role of immunotherapy and checkpoint inhibitors in urothelial cancer at ASCO GU 2016.
00:54
Robert Dreicer, MD of the University of Virginia Health System discusses how Atezolizumab shows very significant activity in advanced urothelial cancer at ASCO GU 2016.

About Genitourinary-Cancer-Meeting


Links
Channel Url: